Standout Papers

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorec... 2004 2026 2011 2018 3.8k
  1. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer (2004)
    David Cunningham, Yves Humblet et al. New England Journal of Medicine

Immediate Impact

4 by Nobel laureates 3 from Science/Nature 164 standout
Sub-graph 1 of 14

Citing Papers

Breast cancer
2021 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
1 intermediate paper

Works of David Khayat being referenced

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
2013
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout

Author Peers

Author Last Decade Papers Cites
David Khayat 5160 2557 2334 103 8.2k
Roscoe F. Morton 4512 1851 1943 97 7.6k
Christopher Stroh 5522 2458 1981 76 7.8k
Tae‐You Kim 4224 2480 1973 183 7.4k
J. Randolph Hecht 6948 2627 2412 115 9.0k
Barth Hoogstraten 4836 2978 1442 78 9.4k
Chris J. O’Callaghan 6112 2829 1271 106 8.8k
Thomas H. Cartwright 7134 2939 3317 81 11.0k
Hans Prenen 3897 2558 2584 202 8.3k
Otilia Dalesio 4373 3819 1472 103 7.9k
Robert W. Ross 6050 3472 3883 61 10.9k

All Works

Loading papers...

Rankless by CCL
2026